Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
NCT05934838Phase 1Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL), sponsored by Weill Cornell Medicine. Primary endpoint: Number of participants who experience adverse events classified per CTCAEv5 at 13 months. Started Oct 2023; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05934838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934838.